Demographical, clinical, and laboratory data for the 79 patients included in the study
| Patient characteristics . | Observation . | Plus cGVHD . | Minus cGVHD . | |
|---|---|---|---|---|
| Total | 79 | 50 | 29 | |
| Demographic data and disease history | ||||
| Gender (numbers, male/female) | 46/33 | 29/21 | 17/12 | |
| Age (years, median, and range) | 49 (15-71) | 52 (17-71) | 44 (15-61) | |
| Height (cm, median, and range) | 173 (149-193) | 174 (153-190) | 172 (149-193) | |
| Weight (kg, median, and range) | 73 (42-133) | 75 (47-133) | 67 (42-110) | |
| BMI (kg/m2, median, and range) | 23.7 (16.9-39.7) | 24.8 (17.9-39.7) | 22.1 (16.9-31) | |
| Diagnosis (numbers) | AML/MDS | 50 | 36 | 14 |
| ALL | 16 | 9 | 7 | |
| MF | 5 | 2 | 3 | |
| MDS/MPN | 4 | 3 | 1 | |
| CLL | 2 | 0 | 2 | |
| AA HL | 1 1 | 0 0 | 1 1 | |
| Conditioning regimen (numbers) | BU + CY | 43 | 28 | 15 |
| FLU + BU | 14 | 10 | 4 | |
| FLU + TRE | 11 | 8 | 3 | |
| FLU + BU + ATG | 3 | 2 | 1 | |
| TBI + ETO | 2 | 0 | 2 | |
| TBI + CY | 2 | 1 | 1 | |
| FLU + CY | 2 | 0 | 2 | |
| CY + ATG | 1 | 0 | 1 | |
| BEAM | 1 | 1 | 0 | |
| Previously aGVHD | 30 | 25 | 5 | |
| Laboratory data 1-year control | Hemoglobin g/dL | 12.7 (8.0-16.3) | 12.7 (9.1-15.6) | 12.6 (8.0-16.3) |
| Leukocytes × 109/L | 6.1 (1.6-12.8) | 7.0 (3.0-12.8) | 5.3 (1.6-11.7) | |
| Neutrophils × 109/L | 3.3 (0.6-9.2) | 3.8 (1.1-9.2) | 2.7 (0.6-5.8) | |
| Platelets × 109/L | 203 (20-385) | 209 (20-385) | 201 (22-354) | |
| CRP mg/L | 3 (1-120) | 3 (1-120) | 2 (1-42) | |
| Albumin g/L | 42 (28-50) | 42 (28-50) | 43.5 (39-50) | |
| Bilirubin µmol/L | (3-129) | 8 (3-129) | 6 (3-16) | |
| cGVHD debut after allo-HSCT | 3-6 mo 6-9 mo 9-12 mo Overlap syndrome | 17 6 16 11 | ||
| cGVHD organ involvement (numbers) | Liver/bile duct Skin GI tract Eyes | 26 22 21 21 | ||
| Mouth | 17 | |||
| Lungs | 3 | |||
| UG tract | 3 | |||
| Musculoskeletal | 1 | |||
| Patient characteristics . | Observation . | Plus cGVHD . | Minus cGVHD . | |
|---|---|---|---|---|
| Total | 79 | 50 | 29 | |
| Demographic data and disease history | ||||
| Gender (numbers, male/female) | 46/33 | 29/21 | 17/12 | |
| Age (years, median, and range) | 49 (15-71) | 52 (17-71) | 44 (15-61) | |
| Height (cm, median, and range) | 173 (149-193) | 174 (153-190) | 172 (149-193) | |
| Weight (kg, median, and range) | 73 (42-133) | 75 (47-133) | 67 (42-110) | |
| BMI (kg/m2, median, and range) | 23.7 (16.9-39.7) | 24.8 (17.9-39.7) | 22.1 (16.9-31) | |
| Diagnosis (numbers) | AML/MDS | 50 | 36 | 14 |
| ALL | 16 | 9 | 7 | |
| MF | 5 | 2 | 3 | |
| MDS/MPN | 4 | 3 | 1 | |
| CLL | 2 | 0 | 2 | |
| AA HL | 1 1 | 0 0 | 1 1 | |
| Conditioning regimen (numbers) | BU + CY | 43 | 28 | 15 |
| FLU + BU | 14 | 10 | 4 | |
| FLU + TRE | 11 | 8 | 3 | |
| FLU + BU + ATG | 3 | 2 | 1 | |
| TBI + ETO | 2 | 0 | 2 | |
| TBI + CY | 2 | 1 | 1 | |
| FLU + CY | 2 | 0 | 2 | |
| CY + ATG | 1 | 0 | 1 | |
| BEAM | 1 | 1 | 0 | |
| Previously aGVHD | 30 | 25 | 5 | |
| Laboratory data 1-year control | Hemoglobin g/dL | 12.7 (8.0-16.3) | 12.7 (9.1-15.6) | 12.6 (8.0-16.3) |
| Leukocytes × 109/L | 6.1 (1.6-12.8) | 7.0 (3.0-12.8) | 5.3 (1.6-11.7) | |
| Neutrophils × 109/L | 3.3 (0.6-9.2) | 3.8 (1.1-9.2) | 2.7 (0.6-5.8) | |
| Platelets × 109/L | 203 (20-385) | 209 (20-385) | 201 (22-354) | |
| CRP mg/L | 3 (1-120) | 3 (1-120) | 2 (1-42) | |
| Albumin g/L | 42 (28-50) | 42 (28-50) | 43.5 (39-50) | |
| Bilirubin µmol/L | (3-129) | 8 (3-129) | 6 (3-16) | |
| cGVHD debut after allo-HSCT | 3-6 mo 6-9 mo 9-12 mo Overlap syndrome | 17 6 16 11 | ||
| cGVHD organ involvement (numbers) | Liver/bile duct Skin GI tract Eyes | 26 22 21 21 | ||
| Mouth | 17 | |||
| Lungs | 3 | |||
| UG tract | 3 | |||
| Musculoskeletal | 1 | |||
Values are, unless otherwise stated, given as median and range in parentheses. Height and weight were registered at the start of conditioning therapy.
AA, aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; ATG, antithymoglobulin; BMI, body mass index; BU, busulphan; CLL, chronic lymphocytic leukemia; CRP, C-reactive protein; CY, cyclophosphamide; ETO, etoposide; FLU, fludarabine; FLU, fludarabine; HL, Hodgkin’s lymphoma; MDS/MPN, myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes; MF, myelofibrosis; TBI, total body irradiation; TRE, treosulfan; UG; urogenital.